Cambridge Healthtech Institute’s 11th Annual

Clinical and Translational Biomarkers

Part of 16th Annual Biomarker World Congress

June 15, 2021

 

The promise of precision medicine has been driven by the need to accurately predict patient response to therapy while ensuring drug efficacy and safety. Reducing costs and the time required for drug development is also a driving force in the use of biomarkers. Cambridge Healthtech Institute’s 11th Annual Clinical & Translational Biomarkers conference will cover novel biomarker discovery, clinical and analytical biomarker validation, and the role of biomarkers in clinical trial design and decision making.

 

Coverage will include, but is not limited to:

 

  • Biomarker discovery and translation
  • Biomarker assay development
  • Biomarkers for safety assessment
  • Genomic biomarkers
  • Biomarker-based clinical trial design
  • Qualification for biomarkers in clinical trials
  • Biomarkers for patient selection
  • Biomarkers to monitor response to therapy
  • Liquid biopsy in oncology clinical trials
  • Precision medicine

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is January 29, 2021.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:

Julia Boguslavsky

Executive Director, Conferences

Cambridge Healthtech Institute

Email: juliab@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: 781-247-6286

Email: reymael@healthtech.com